Antiangiogenesis: current clinical data and future perspectives

Drevs, J. and Laus, C. and Medinger, M. and Schmidt-Gersbach, C. and Unger, C.. (2002) Antiangiogenesis: current clinical data and future perspectives. Onkologie, 25 (6). pp. 520-527.

PDF - Published Version

Official URL: http://edoc.unibas.ch/43942/

Downloads: Statistics Overview


Neovascularization is a prerequisite for progressive growth of solid tumors and their metastases. This process is tightly regulated by a large number of proangiogenic and antiangiogenic factors such as VEGF, bFGF and matrix-metalloproteinases. The inhibition of angiogenesis is an innovative therapeutic approach and could represent a powerful adjunct to traditional therapy of malignant tumors. Preclinical trials have been very successful but in clinical studies meaningful response rates could only be shown in some cases. This might indicate the existence of different angiogenic phenotypes in humans. It seems that at present only a part of the interactions between the angiogenic cytokines are known. In addition, new receptor/ligand systems which regulate the neovascularization are being described. This article presents an overview of the most important angiogenically active substances, preclinical and clinical data, surrogate markers as well as future perspectives.
Faculties and Departments:03 Faculty of Medicine
UniBasel Contributors:Medinger, Michael
Item Type:Article, refereed
Article Subtype:Research Article
Publisher:Karger Publishers
Note:Publication type according to Uni Basel Research Database: Journal article
Identification Number:
edoc DOI:
Last Modified:24 Oct 2017 10:09
Deposited On:04 Oct 2017 08:04

Repository Staff Only: item control page